Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2015.664 | A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.366 | MicroRNAs as biomarkers for predicting the effect of anti-TNF and anti-IL6 in changes of bone erosions in rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.446 | A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2017.633 | An exploratory maintenance trial evaluating the effect of BI 655064 in Lupus Nephritis patients who have achieved a meaningful response either at the end of 1293.10 or after an induction treatment outside of 1293.10 |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2016.037 | Identification and validation of microRNAs associated with inflammation detected by magnetic resonance imaging in patients with early rheumatoid arthritis. |
Prof. TAM Lai Shan 譚麗珊 |
| 2013.451 | Immunopathological roles of the novel inflammatory cytokine interleukin-36 in the patients with systemic lupus erythematous | Professor TAM Lai Shan |
| 2016.533 | A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate |
Prof. TAM Lai Shan 譚麗珊 |
| 2015.334 | Characterization of the potential role of interleukin-36 (IL-36) in regulating protective and pathogenic B cells in systemic lupus erythematosus |
Dr. TAM Lai Shan 譚麗珊 |
| 2017.700 | Circulating microRNA 99b as biomarker for predicting the early development, repair and progression of bone erosions in early rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2015.214 | Prevalence and risk factors for osteoporosis in patients with ankylosing spondylitis in Hong Kong: a cross-sectional cohort study |
Dr. TAM Lai Shan 譚麗珊 |
| 2017.295 | The long term renal outcome of biopsy proven paediatric lupus nephritis - a comparison of local and overseas cohort |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.431 | Effect of RANKL inhibition on healing of bone erosion in rheumatoid arthritis using HR-pQCT |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.551 | A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison with Mycophenolate Mofetil and Corticosteroids in Subjects with Class III/IV±V Lupus Nephritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2013.300 | Immunopathological roles of the novel anti-inflammatory cytokine interleukin-35 in the patients with systemic lupus erythematous | Professor TAM Lai Shan |
| 2017.605 | Evaluation of molecular and cellular dysregulation in systemic lupus erythematosus | Prof. TAM Lai Shan |
| 2016.451 | Prevention of metacarpophalangeal joints structure damage in patients with psoriatic arthritis using secukinumab |
Prof. TAM Lai Shan 譚麗珊 |
| 2016.390 | Assessment of structure changes after 4 years on the second and third metacarpophalangeal joint and distal radius in patients with psoriatic arthritis – a follow-up study using High-resolution peripheral quantitative CT (HR-pQCT) |
Prof. TAM Lai Shan 譚麗珊 |
| 2013.469 | The Clinical Rheumatology Systematic Treat-to-target in Asia Leadership (CRYSTAL) Project | Prof. TAM Lai Shan |
| 2016.450 | Cost Effectiveness Analysis of Biologic Therapies for the Treatment of Rheumatoid Arthritis in Hong Kong |
Prof. TAM Lai Shan 譚麗珊教授 |
| 2019.247 | Survival benefit of statin use in patients with immune mediated inflammatory diseases in Hong Kong - A population-based study | Prof. TAM Lai Shan |
| 2020.704 | Bone Erosion Volume Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of disability in patients with rheumatoid arthritis | Prof. TAM Lai Shan |
| 2019.063 | Effects of tight-control strategy with rosuvastatin on progression of subclinical carotid and coronary atherosclerosis in psoriatic arthritis- a prospective cohort study |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.617 | Subclinical atherosclerosis in axial spondyloarthritis- a cross-sectional study |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.530 | 5-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients who received Treat-to-Target Management: a population-based cohort study |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.129 | Vascular effects of achieving low disease activity in axial spondyloarthritis - a 2-year prospective cohort study |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.224 | Effects of achieving SDAI remission on joint space outcomes progression in early rheumatoid arthritis: an HR-pQCT study |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.180 | The microbiome study in psoriasis and psoriatic arthropathy patients in Hong Kong |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.519 | Cardiovascular events in axial spondyloarthritis |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.573 | Subclinical gut inflammation and gut microbiome in axial spondyloarthritis patients in Hong Kong |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.401 | Immunological role of the ILC2-B lymphocyte regulatory axis in systemic lupus erythematosus |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.141 | Quantification of erosion, joint space width and new bone formation using deep learning-based approaches |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.540 | A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE). |
Dr. TAM Lai Shan 譚麗珊 |
| 2018.225 | The APLAR Spondyloarthritis (SpA) Registry |
Prof. TAM Lai Shan 譚麗珊 |
| 2018.417 | Prevention of metacarpophalangeal joints structure damage in patients with psoriatic arthritis using tofacitinib | Prof. TAM Lai Shan |
| 2019.264 | Incidence of and associated factors of infective complications in rheumatology patients taking DMARDs | Dr. TAM Lai Shan |
| 2020.516 | CUHK Rheumatology Research Centre Imaging Database of Rheumatic Diseases |
Prof. TAM Lai Shan 譚麗珊 |
| 2020.128 | Portable integrated diagnostic platform for chronic auto-immune diseases |
Prof. TAM Lai Shan 譚麗珊 |
| 2018.144 | Bone Microarchitecture Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) as predictor of fracture risk in patients with glucocorticoid-induced osteoporosis |
Prof. TAM Lai Shan 譚麗珊 |
| 2019.650 | Effects of tight-control strategy with and without rosuvastatin on progression of subclinical coronary and carotid atherosclerosis in psoriatic arthritis- a randomized placebo-controlled study |
Prof. TAM Lai Shan 譚麗珊 |
| 2009.583 | Function and expression profile of the nucleotide-blinding and oligoerization domain (NOD)-2 receptors in systemic lupus erythematosus | Prof Tam Lai Shan |
| 2010.191 | Human Papillomavirus infection and cervical intraepithelial neoplasia in patients with systemic lupus erythematosus- the role of toll-like receptors | Professor TAM Lai Shan |
| 2011.031 | The role of HMGB1 in the pathogenesis of systemic lupus erythematosus | Professor TAM Lai Shan |
| 2014.052 | Advanced 3-D Bioimaging Technology to improve vertebral fracture prediction in patients with glucocorticoid-induced osteoporosis | Prof. TAM Lai Shan |
| 2008.475 | Innate pathogen recognition in systemic lupus erythematosus: Toll-like receptors and NOD-like receptors | Prof Tam Lai Shan |
| 2010.250 | HMGB1: a danger signal molecule of the innate immune response for the immunopathogenesis of systemic lupus erythematosus | Professor TAM Lai Shan |
| 2011.547 | The role of Receptor for Advanced Glycation End Products (RAGE) in the pathogenesis of systemic Lupus erythematosus (SLE) | Professor TAM Lai Shan |
| 2012.478 | Vascular effects of achieving minimal disease activity iin psoriatic arthritis - a 2 year prospetive cohort study | Prof. TAM Lai Shan |
| 2023.189 | Survey of cardiovascular disease Risk Factors in Psoriatic Arthritis | Prof. TAM Lai Shan |
| 2021.568 | A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease |
Prof. TAM Lai Shan 譚麗珊 |
| 2022.151 | Osteosarcopenia Assessed by 3D High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) and fracture risk in non-osteoporotic patients with immune-mediated inflammatory disease |
Prof. TAM Lai Shan 譚麗珊 |
Page 194 of 254.